Potassium Chloride
Potassium Chloride Prescribing Information
Potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium chloride extended-release tablets, USP are supplied as:
600 mg (8 mEq) are film coated, round white, tablets debossed with “T229”
750 mg (10 mEq) are film coated, round yellow, tablets debossed with “T230”
Potassium chloride is contraindicated in patients on triamterene and amiloride.
The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.
There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation.
Skin rash has been reported rarely.
Potassium Chloride Extended-release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet.
Potassium Chloride Extended-release Tablets, USP are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.
Inactive Ingredients: Paraffin wax pastilles, ethylcellulose, triethyl citrate, colloidal silicon dioxide, and magnesium stearate. White tablets also contain polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, and talc. Yellow tablets also contain polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, D&C Yellow No. 10 aluminum lake, and FD&C Yellow No. 6 aluminum lake.
FDA approved dissolution test specifications differ from USP
FDA approved acceptance criteria for assay differs from USP test
Potassium chloride extended-release tablets, USP contain 600 mg or 750 mg of potassium chloride (equivalent to 8 mEq and 10 mEq respectively. Potassium chloride extended-release tablets, USP are provided as extended release tablets.
Dose | Shpae | Color | Debossment | NDC#: 24979-xxx-xx | |
Bottle of 100 tablets | Bottle of 1,000 tablets | ||||
600 mg (8 mEq) | round | white | T229 | 229-01 | 229-03 |
750 mg (10 mEq) | round | yellow | T230 | 230-01 | 230-03 |
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.]. Protect from light and moisture.
Dispense in a tight, light-resistant container.